Hepatic stellate cells induce hepatocellular carcinoma cell resistance to sorafenib through the laminin-332/α3 integrin axis recovery of focal adhesion kinase ubiquitination

Laminin-332 sustains chemoresistance and quiescence as part of the human hepatic cancer stem cell niche

(2016) Olivier Govaere et al.   JOURNAL OF HEPATOLOGY

Molecular Mechanism and Prediction of Sorafenib Chemoresistance in Human Hepatocellular Carcinoma

(2015) Naoshi Nishida et al.   DIGESTIVE DISEASES

Focal adhesion signaling and therapy resistance in cancer

(2015) Iris Eke et al.   SEMINARS IN CANCER BIOLOGY

Moving towards personalised therapy in patients with hepatocellular carcinoma: the role of the microenvironment

(2014) Gianluigi Giannelli et al.   GUT

A mesenchymal-like phenotype and expression of CD44 predict lack of apoptotic response to sorafenib in liver tumor cells

(2014) Joan Fernando et al.   INTERNATIONAL JOURNAL OF CANCER

Stellate cells and the development of liver cancer: Therapeutic potential of targeting the stroma

(2014) Cédric Coulouarn et al.   JOURNAL OF HEPATOLOGY

Molecular profiling of stroma identifies osteopontin as an independent predictor of poor prognosis in intrahepatic cholangiocarcinoma

(2013) Laurent Sulpice et al.   HEPATOLOGY

Plasma Biomarkers as Predictors of Outcome in Patients with Advanced Hepatocellular Carcinoma

(2012) J. M. Llovet et al.   CLINICAL CANCER RESEARCH

Pancreatic Stellate Cells Radioprotect Pancreatic Cancer Cells through  1-Integrin Signaling

(2011) T. S. Mantoni et al.   CANCER RESEARCH

Hepatic stellate cells stimulate HCC cell migration via laminin-5 production

(2011) Angela Santamato et al.   CLINICAL SCIENCE

Disruption of Laminin-Integrin-CD151-Focal Adhesion Kinase Axis Sensitizes Breast Cancer Cells to ErbB2 Antagonists

(2010) X. H. Yang et al.   CANCER RESEARCH

Tumor cell-specific bioluminescence platform to identify stroma-induced changes to anticancer drug activity

(2010) Douglas W McMillin et al.   NATURE MEDICINE

Update on the pathophysiology of liver fibrosis

(2010) Massimo Pinzani et al.   Expert Review of Gastroenterology & Hepatology

Matrix Crosslinking Forces Tumor Progression by Enhancing Integrin Signaling

(2009) Kandice R. Levental et al.   CELL

Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial

(2008) Ann-Lii Cheng et al.   LANCET ONCOLOGY

Sorafenib in Advanced Hepatocellular Carcinoma

(2008) Josep M. Llovet et al.   NEW ENGLAND JOURNAL OF MEDICINE